Skip to main content
SpringerLink
Log in

Secondary Neoplasms Following Treatment for Brain Tumors

  • Chapter
  • First Online:
Late Effects of Treatment for Brain Tumors

Part of the book series: Cancer Treatment and Research ((CTAR,volume 150))

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bhatia S, Sklar C. Second cancers in survivors of childhood cancer. Nature Rev. 2002;2:124–132.

    Google Scholar 

  2. Neugut AI, Meadows, AT, Robinson E, ed. Multiple Primary Cancers. 1st ed. Philadelphia: Lippincott Williams & Wilkins; 1999.

    Google Scholar 

  3. Li FP, Cassady JR, Jaffe N. Risk of second tumors in survivors of childhood cancer. Cancer. 1975;35:1230–1235.

    PubMed  CAS  Google Scholar 

  4. Meadows AT, Baum E, Fossati-Bellani F, et al. Second malignant neoplasms in children: an update from the Late Effects Study Group. J Clin Oncol. 1985;3:532–538.

    PubMed  CAS  Google Scholar 

  5. Hawkins MM, Draper GJ, Kingston JE. Incidence of second primary tumours among childhood cancer survivors. Br J Cancer. 1987;56:339–347.

    PubMed  CAS  Google Scholar 

  6. Blatt J, Olshan A, Gula MJ, et al. Second malignancies in very-long-term survivors of childhood cancer. Am J Med. 1992;93:57–60.

    PubMed  CAS  Google Scholar 

  7. de Vathaire F, Hawkins M, Campbell S, et al. Second malignant neoplasms after a first cancer in childhood: temporal pattern of risk according to type of treatment. Br J Cancer. 1999;79:1884–1893.

    PubMed  Google Scholar 

  8. de Vathaire F, Schweisguth O, Rodary C, et al. Long-term risk of second malignant neoplasm after a cancer in childhood. Br J Cancer. 1989;59:448–452.

    PubMed  Google Scholar 

  9. Neglia JP, Friedman DL, Yasui Y, et al. Second malignant neoplasms in five-year survivors of childhood cancer: childhood cancer survivor study. J Natl Cancer Inst. 2001;93:618–629.

    PubMed  CAS  Google Scholar 

  10. Jenkinson HC, Hawkins MM, Stiller CA, et al. Long-term population-based risks of second malignant neoplasms after childhood cancer in Britain. Br J Cancer. 2004;91:1905–1910.

    PubMed  CAS  Google Scholar 

  11. Knudson AG, Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA. 1971;68:820–823.

    PubMed  Google Scholar 

  12. Narod SA, Stiller C, Lenoir GM. An estimate of the heritable fraction of childhood cancer. Br J Cancer. 1991;63:993–999.

    PubMed  CAS  Google Scholar 

  13. Ferner RE. Neurofibromatosis 1 and neurofibromatosis 2: a twenty first century perspective. Lancet Neurol. 2007;6:340–351.

    PubMed  Google Scholar 

  14. Inskip PD, Curtis RE. New malignancies following childhood cancer in the United States, 1973–2002. Int J Cancer. 2007;121:2233–2240.

    PubMed  CAS  Google Scholar 

  15. Olsen JH, Garwicz S, Hertz H, et al. Second malignant neoplasms after cancer in childhood or adolescence. Nordic Society of Paediatric Haematology and Oncology Association of the Nordic Cancer Registries. BMJ (Clin Res) ed. 1993;307:1030–1036.

    PubMed  CAS  Google Scholar 

  16. MacArthur AC, Spinelli JJ, Rogers PC, et al. Risk of a second malignant neoplasm among 5-year survivors of cancer in childhood and adolescence in British Columbia, Canada. Pediatr Blood Cancer. 2007;48:453–459.

    PubMed  Google Scholar 

  17. Pizzo PA, Poplack, DG, ed. Principles & Practice of Pediatric Oncology. 5th ed: Philadelphia: Lippincott Williams & Wilkins; 2005.

    Google Scholar 

  18. Jenkin D. Long-term survival of children with brain tumors. Oncology (Williston Park, NY). 1996;10:715–719; discussion 20, 22, 28.

    CAS  Google Scholar 

  19. Devarahally SR, Severson RK, Chuba P, et al. Second malignant neoplasms after primary central nervous system malignancies of childhood and adolescence. Pediatr Hematol Oncol. 2003;20:617–625.

    PubMed  Google Scholar 

  20. Bhatia S, Yasui Y, Robison LL, et al. High risk of subsequent neoplasms continues with extended follow-up of childhood Hodgkin's disease: report from the Late Effects Study Group. J Clin Oncol. 2003;21:4386–4394.

    PubMed  Google Scholar 

  21. Hijiya N, Hudson MM, Lensing S, et al. Cumulative incidence of secondary neoplasms as a first event after childhood acute lymphoblastic leukemia. JAMA. 2007;297:1207–1215.

    PubMed  CAS  Google Scholar 

  22. Smith MB, Xue H, Strong L, et al. Forty-year experience with second malignancies after treatment of childhood cancer: analysis of outcome following the development of the second malignancy. J Pediatr Surg. 1993;28:1342–1348; discussion 8–9.

    PubMed  CAS  Google Scholar 

  23. Cardous-Ubbink MC, Heinen RC, Bakker PJ, et al. Risk of second malignancies in long-term survivors of childhood cancer. Eur J Cancer. 2007;43:351–362.

    PubMed  CAS  Google Scholar 

  24. Corpron CA, Black CT, Ross MI, et al. Melanoma as a second malignant neoplasm after childhood cancer. Am J Surg. 1996;172:459–461; discussion 61–62.

    PubMed  CAS  Google Scholar 

  25. Garwicz S, Anderson H, Olsen JH, et al. Second malignant neoplasms after cancer in childhood and adolescence: a population-based case-control study in the 5 Nordic countries. The Nordic Society for Pediatric Hematology and Oncology. The Association of the Nordic Cancer Registries. Int J Cancer. 2000;88:672–678.

    PubMed  CAS  Google Scholar 

  26. Li FP, Myers MH, Heise HW, et al. The course of five-year survivors of cancer in childhood. J Pediatr. 1978;93:185–187.

    PubMed  CAS  Google Scholar 

  27. Baker KS, DeFor TE, Burns LJ, et al. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol. 2003;21:1352–1358.

    PubMed  Google Scholar 

  28. Neuget AI, Meadows AT, Robinson E, ed. Multiple Primary Cancers. Philadelphia: Lippincott Williams & Wilkins; 1999.

    Google Scholar 

  29. Sankila R, Pukkala E, Teppo L. Risk of subsequent malignant neoplasms among 470,000 cancer patients in Finland, 1953–1991. Int J Cancer. 1995;60:464–470.

    PubMed  CAS  Google Scholar 

  30. Dong C, Hemminki K. Second primary neoplasms in 633,964 cancer patients in Sweden, 1958–1996. Int J Cancer. 2001;93:155–161.

    PubMed  CAS  Google Scholar 

  31. Curtis RE, Boice JD, Jr., Kleinerman RA, et al. Summary: multiple primary cancers in Connecticut, 1935–82. Natl Cancer Inst Monograph. 1985;68:219–242.

    CAS  Google Scholar 

  32. Peterson KM, Shao C, McCarter R, et al. An analysis of SEER data of increasing risk of secondary malignant neoplasms among long-term survivors of childhood brain tumors. Pediatr Blood Cancer. 2006;47:83–88.

    PubMed  Google Scholar 

  33. Neglia JP, Robison LL, Stovall M, et al. New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2006;98:1528–1537.

    PubMed  Google Scholar 

  34. Duffner PK, Krischer JP, Horowitz ME, et al. Second malignancies in young children with primary brain tumors following treatment with prolonged postoperative chemotherapy and delayed irradiation: a Pediatric Oncology Group study. Ann Neurol. 1998;44:313–316.

    PubMed  CAS  Google Scholar 

  35. Anderson DM, Rennie KM, Ziegler RS, et al. Medical and neurocognitive late effects among survivors of childhood central nervous system tumors. Cancer. 2001;92:2709–2719.

    PubMed  CAS  Google Scholar 

  36. Bhatia S. Late effects among survivors of leukemia during childhood and adolescence. Blood Cells Mol Dis. 2003;31:84–92.

    PubMed  Google Scholar 

  37. Albright AL. Pediatric brain tumors. CA: A Cancer J Clin. 1993;43:272–288.

    CAS  Google Scholar 

  38. Broniscer A, Ke W, Fuller CE, et al. Second neoplasms in pediatric patients with primary central nervous system tumors: the St. Jude Children's Research Hospital experience. Cancer. 2004;100:2246–2252.

    PubMed  Google Scholar 

  39. Buyukpamukcu M, Varan A, Yazici N, et al. Second malignant neoplasms following the treatment of brain tumors in children. J Child Neurol. 2006;21:433–436.

    PubMed  Google Scholar 

  40. Fisher PG, Jenab J, Gopldthwaite PT, et al. Outcomes and failure patterns in childhood craniopharyngiomas. Childs Nerv Syst. 1998;14:558–563.

    PubMed  CAS  Google Scholar 

  41. Donaldson SS, Hancock SL. Second cancers after Hodgkin's disease in childhood. N Engl J Med. 1996;334:792–794.

    PubMed  CAS  Google Scholar 

  42. Inskip HM, Kinlen LJ, Taylor AM, et al. Risk of breast cancer and other cancers in heterozygotes for ataxia-telangiectasia. Br J Cancer. 1999;79:1304–1307.

    PubMed  CAS  Google Scholar 

  43. Caglar K, Varan A, Akyuz C, et al. Second neoplasms in pediatric patients treated for cancer: a center's 30-year experience. J Pediatr Hematol Oncol. 2006;28:374–378.

    PubMed  Google Scholar 

  44. Nichols KE, Malkin D, Garber JE, et al. Germ-line p53 mutations predispose to a wide spectrum of early-onset cancers. Cancer Epidemiol Biomarkers Prev. 2001;10:83–87.

    PubMed  CAS  Google Scholar 

  45. Evans SC, Lozano G. The Li-Fraumeni syndrome: an inherited susceptibility to cancer. Mol Med Today. 1997;3:390–395.

    PubMed  CAS  Google Scholar 

  46. Strong LC, Knudson AG, Jr. Letter: Second cancers in retinoblastoma. Lancet. 1973;2:1086.

    PubMed  CAS  Google Scholar 

  47. Kenney LB, Yasui Y, Inskip PD, et al. Breast cancer after childhood cancer: a report from the Childhood Cancer Survivor Study. Ann Int Med. 2004;141:590–597.

    PubMed  Google Scholar 

  48. Bassal M, Mertens AC, Taylor L, et al. Risk of selected subsequent carcinomas in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2006;24:476–483.

    PubMed  Google Scholar 

  49. Kimonis VE, Goldstein AM, Pastakia B, et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet. 1997;69:299–308.

    PubMed  CAS  Google Scholar 

  50. Walter AW, Pivnick EK, Bale AE, et al. Complications of the nevoid basal cell carcinoma syndrome: a case report. J Pediatr Hematol Oncol. 1997;19:258–262.

    PubMed  CAS  Google Scholar 

  51. Meadows AT. Retinoblastoma survivors: sarcomas and surveillance. J Natl Cancer Inst. 2007;99:3–5.

    PubMed  Google Scholar 

  52. Kleinerman RA, Tucker MA, Abramson DH, et al. Risk of soft tissue sarcomas by individual subtype in survivors of hereditary retinoblastoma. J Natl Cancer Inst. 2007;99:24–31.

    PubMed  Google Scholar 

  53. Kleinerman RA, Tucker MA, Tarone RE, et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol. 2005;23:2272–2279.

    PubMed  Google Scholar 

  54. Wong FL, Boice JD, Jr., Abramson DH, et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA. 1997;278:1262–1267.

    PubMed  CAS  Google Scholar 

  55. Inskip PD. Multiple primary tumors involving cancer of the brain and central nervous system as the first or subsequent cancer. Cancer. 2003;98:562–570.

    PubMed  Google Scholar 

  56. Sklar CA. Overview of the effects of cancer therapies: the nature, scale and breadth of the problem. Acta Paediatr Suppl. 1999;88:1–4.

    PubMed  CAS  Google Scholar 

  57. Nicholson HS, Fears TR, Byrne J. Death during adulthood in survivors of childhood and adolescent cancer. Cancer. 1994;73:3094–3102.

    PubMed  CAS  Google Scholar 

  58. Green DM, Zevon MA, Reese PA, et al. Factors that influence the further survival of patients who survive for five years after the diagnosis of cancer in childhood or adolescence. Med Pediatr Oncol. 1994;22:91–96.

    PubMed  CAS  Google Scholar 

  59. Mertens AC, Yasui Y, Neglia JP, et al. Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol. 2001;19:3163–3172.

    PubMed  CAS  Google Scholar 

  60. Robertson CM, Hawkins MM, Kingston JE. Late deaths and survival after childhood cancer: implications for cure. BMJ (Clin Res) ed. 1994;309:162–166.

    PubMed  CAS  Google Scholar 

  61. Hudson MM, Jones D, Boyett J, et al. Late mortality of long-term survivors of childhood cancer. J Clin Oncol. 1997;15:2205–2213.

    PubMed  CAS  Google Scholar 

  62. Lawless SC, Verma P, Green DM, et al. Mortality experiences among 15+ year survivors of childhood and adolescent cancers. Pediatr Blood Cancer. 2007;48:333–338.

    PubMed  Google Scholar 

  63. Hoppe RT. Hodgkin's disease: complications of therapy and excess mortality. Ann Oncol. 1997;8 Suppl 1:115–118.

    PubMed  Google Scholar 

  64. Hawkins MM, Kingston JE, Kinnier Wilson LM. Late deaths after treatment for childhood cancer. Arch Dis Child. 1990;65:1356–1363.

    PubMed  CAS  Google Scholar 

  65. Green DM, Hyland A, Chung CS, et al. Cancer and cardiac mortality among 15-year survivors of cancer diagnosed during childhood or adolescence. J Clin Oncol. 1999;17:3207–3215.

    PubMed  CAS  Google Scholar 

  66. Moller TR, Garwicz S, Barlow L, et al. Decreasing late mortality among five-year survivors of cancer in childhood and adolescence: a population-based study in the Nordic countries. J Clin Oncol. 2001;19:3173–3181.

    PubMed  CAS  Google Scholar 

  67. Jenkin D, Greenberg M, Hoffman H, et al. Brain tumors in children: long-term survival after radiation treatment. Int J Radiat Oncol Biol Phys. 1995;31:445–451.

    PubMed  CAS  Google Scholar 

  68. Mertens AC. Cause of mortality in 5-year survivors of childhood cancer. Pediatr Blood Cancer. 2007;48:723–726.

    PubMed  Google Scholar 

  69. Cardous-Ubbink MC, Heinen RC, Langeveld NE, et al. Long-term cause-specific mortality among five-year survivors of childhood cancer. Pediatr Blood Cancer. 2004;42:563–573.

    PubMed  CAS  Google Scholar 

  70. MacArthur AC, Spinelli JJ, Rogers PC, et al. Mortality among 5-year survivors of cancer diagnosed during childhood or adolescence in British Columbia, Canada. Pediatr Blood Cancer. 2007;48:460–467.

    PubMed  Google Scholar 

  71. Tucker MA, D'Angio GJ, Boice JD, Jr., et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med. 1987;317:588–593.

    PubMed  CAS  Google Scholar 

  72. Tucker MA, Meadows AT, Boice JD, Jr., et al. Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst. 1987;78:459–464.

    PubMed  CAS  Google Scholar 

  73. Pui CH. Epipodophyllotoxin-related acute myeloid leukaemia. Lancet. 1991;338:1468.

    PubMed  CAS  Google Scholar 

  74. Eng C, Li FP, Abramson DH, et al. Mortality from second tumors among long-term survivors of retinoblastoma. J Natl Cancer Inst. 1993;85:1121–1128.

    PubMed  CAS  Google Scholar 

  75. Acquaviva A, Ciccolallo L, Rondelli R, et al. Mortality from second tumour among long-term survivors of retinoblastoma: a retrospective analysis of the Italian retinoblastoma registry. Oncogene. 2006;25:5350–5357.

    PubMed  CAS  Google Scholar 

  76. Fletcher O, Easton D, Anderson K, et al. Lifetime risks of common cancers among retinoblastoma survivors. J Natl Cancer Inst. 2004;96:357–363.

    PubMed  Google Scholar 

  77. Abramson DH, Ellsworth RM, Kitchin FD, et al. Second nonocular tumors in retinoblastoma survivors. Are they radiation-induced? Ophthalmology. 1984;91:1351–1355.

    PubMed  CAS  Google Scholar 

  78. Simone JV. Late mortality in childhood cancer: two excellent studies bring good news tempered by room for improvement. J Clin Oncol. 2001;19:3161–3162.

    PubMed  CAS  Google Scholar 

  79. Hudson MM, Mertens AC, Yasui Y, et al. Health status of adult long-term survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. JAMA. 2003;290:1583–1592.

    PubMed  CAS  Google Scholar 

  80. Zebrack BJ, Gurney JG, Oeffinger K, et al. Psychological outcomes in long-term survivors of childhood brain cancer: a report from the childhood cancer survivor study. J Clin Oncol. 2004;22:999–1006.

    PubMed  Google Scholar 

  81. Zebrack BJ, Zevon MA, Turk N, et al. Psychological distress in long-term survivors of solid tumors diagnosed in childhood: a report from the childhood cancer survivor study. Pediatr Blood Cancer. 2007;49:47–51.

    PubMed  Google Scholar 

  82. Gotay CC, Ransom S, Pagano IS. Quality of life in survivors of multiple primary cancers compared with cancer survivor controls. Cancer. 2007;110:2101–2109.

    PubMed  Google Scholar 

  83. Green DM. Late effects of treatment for cancer during childhood and adolescence. Curr Probl Cancer. 2003;27:127–142.

    PubMed  Google Scholar 

  84. Schwartz CL. Long-term survivors of childhood cancer: the late effects of therapy. Oncologist. 1999;4:45–54.

    PubMed  CAS  Google Scholar 

  85. Mike V, Meadows AT, D'Angio GJ. Incidence of second malignant neoplasms in children: results of an international study. Lancet. 1982;2:1326–1331.

    PubMed  CAS  Google Scholar 

  86. Rothman K, Keller A. The effect of joint exposure to alcohol and tobacco on risk of cancer of the mouth and pharynx. J Chronic Dis. 1972;25:711–716.

    PubMed  CAS  Google Scholar 

  87. Tucker MA, Jones PH, Boice JD, Jr., et al. Therapeutic radiation at a young age is linked to secondary thyroid cancer. The Late Effects Study Group. Cancer Res. 1991;51:2885–2888.

    PubMed  CAS  Google Scholar 

  88. Hammal DM, Bell CL, Craft AW, et al. Second primary tumors in children and young adults in the North of England (1968–99). Pediatr Blood Cancer. 2005;45:155–161.

    PubMed  Google Scholar 

  89. Beaty O, 3rd, Hudson MM, Greenwald C, et al. Subsequent malignancies in children and adolescents after treatment for Hodgkin's disease. J Clin Oncol. 1995;13:603–609.

    PubMed  Google Scholar 

  90. Bhatia S, Ramsay NK, Steinbuch M, et al. Malignant neoplasms following bone marrow transplantation. Blood. 1996;87:3633–3639.

    PubMed  CAS  Google Scholar 

  91. Darrington DL, Vose JM, Anderson JR, et al. Incidence and characterization of secondary myelodysplastic syndrome and acute myelogenous leukemia following high-dose chemoradiotherapy and autologous stem-cell transplantation for lymphoid malignancies. J Clin Oncol. 1994;12:2527–2534.

    PubMed  CAS  Google Scholar 

  92. Bhatia S, Robison LL, Oberlin O, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. N Engl J Med. 1996;334:745–751.

    PubMed  CAS  Google Scholar 

  93. Neglia JP, Meadows AT, Robison LL, et al. Second neoplasms after acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;325:1330–1336.

    PubMed  CAS  Google Scholar 

  94. Nygaard R, Garwicz S, Haldorsen T, et al. Second malignant neoplasms in patients treated for childhood leukemia. A population-based cohort study from the Nordic countries. The Nordic Society of Pediatric Oncology and Hematology (NOPHO). Acta Paediatrica Scandinavica. 1991;80:1220–1228.

    PubMed  CAS  Google Scholar 

  95. Walter AW, Hancock ML, Pui CH, et al. Secondary brain tumors in children treated for acute lymphoblastic leukemia at St. Jude Children's Research Hospital. J Clin Oncol. 1998;16:3761–3767.

    PubMed  CAS  Google Scholar 

  96. Shapiro S, Mealey J, Jr., Sartorius C. Radiation-induced intracranial malignant gliomas. J Neurosurg. 1989;71:77–82.

    PubMed  CAS  Google Scholar 

  97. Abramson DH, Frank CM. Second nonocular tumors in survivors of bilateral retinoblastoma: a possible age effect on radiation-related risk. Ophthalmology. 1998;105:573–579; discussion 9–80.

    PubMed  CAS  Google Scholar 

  98. Jenkin D, Angyalfi S, Becker L, et al. Optic glioma in children: surveillance, resection, or irradiation? Int J Radiat Oncol Biol Phys. 1993;25:215–225.

    PubMed  CAS  Google Scholar 

  99. Sussman A, Leviton A, Allred EN, et al. Childhood brain tumor: presentation at younger age is associated with a family tumor history. Cancer Causes Control. 1990;1:75–79.

    PubMed  CAS  Google Scholar 

  100. Levine EG, Bloomfield CD. Leukemias and myelodysplastic syndromes secondary to drug, radiation, and environmental exposure. Semin Oncol. 1992;19:47–84.

    PubMed  CAS  Google Scholar 

  101. Armstrong GT, Sklar CA, Hudson MM, et al. Long-term health status among survivors of childhood cancer: does sex matter? J Clin Oncol. 2007;25:4477–4489.

    PubMed  Google Scholar 

  102. Sklar C, Whitton J, Mertens A, et al. Abnormalities of the thyroid in survivors of Hodgkin's disease: data from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2000;85:3227–3232.

    PubMed  CAS  Google Scholar 

  103. Sigurdson AJ, Ronckers CM, Mertens AC, et al. Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study. Lancet. 2005;365:2014–2023.

    PubMed  Google Scholar 

  104. Zang EA, Wynder EL. Differences in lung cancer risk between men and women: examination of the evidence. J Natl Cancer Inst. 1996;88:183–192.

    PubMed  CAS  Google Scholar 

  105. Ganjavi H, Malkin D. Genetics of childhood cancer. Clin Orthop Relat Res 2002:75–87.

    Google Scholar 

  106. Stratton MR, Williams S, Fisher C, et al. Structural alterations of the RB1 gene in human soft tissue tumours. Br J Cancer. 1989;60:202–205.

    PubMed  CAS  Google Scholar 

  107. Eng C, Ponder BA. The role of gene mutations in the genesis of familial cancers. FASEB J. 1993;7:910–919.

    PubMed  CAS  Google Scholar 

  108. Lohmann DR, Gerick M, Brandt B, et al. Constitutional RB1-gene mutations in patients with isolated unilateral retinoblastoma. Am J Human Genet. 1997;61:282–294.

    CAS  Google Scholar 

  109. Klutz M, Horsthemke B, Lohmann DR. RB1 gene mutations in peripheral blood DNA of patients with isolated unilateral retinoblastoma. Am J Human Genet. 1999;64:667–668.

    CAS  Google Scholar 

  110. Farwell J, Flannery JT. Cancer in relatives of children with central-nervous-system neoplasms. N Engl J Med. 1984;311:749–753.

    PubMed  CAS  Google Scholar 

  111. Larson RA, Wang Y, Banerjee M, et al. Prevalence of the inactivating 609C→T polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood. 1999;94:803–807.

    PubMed  CAS  Google Scholar 

  112. Naoe T, Takeyama K, Yokozawa T, et al. Analysis of genetic polymorphism in NQO1, GST-M1, GST-T1, and CYP3A4 in 469 Japanese patients with therapy-related leukemia/ myelodysplastic syndrome and de novo acute myeloid leukemia. Clin Cancer Res. 2000;6:4091–4095.

    PubMed  CAS  Google Scholar 

  113. Felix CA. Secondary leukemias induced by topoisomerase-targeted drugs. Biochimica et Biophysica Acta. 1998;1400:233–255.

    PubMed  CAS  Google Scholar 

  114. Allan JM, Wild CP, Rollinson S, et al. Polymorphism in glutathione S-transferase P1 is associated with susceptibility to chemotherapy-induced leukemia. Proc Natl Acad Sci USA. 2001;98:11592–11597.

    PubMed  CAS  Google Scholar 

  115. Felix CA, Walker AH, Lange BJ, et al. Association of CYP3A4 genotype with treatment-related leukemia. Proc Natl Acad Sci USA. 1998;95:13176–13181.

    PubMed  CAS  Google Scholar 

  116. Woo MH, Shuster JJ, Chen C, et al. Glutathione S-transferase genotypes in children who develop treatment-related acute myeloid malignancies. Leukemia. 2000;14:232–237.

    PubMed  CAS  Google Scholar 

  117. Perentesis JP. Genetic predisposition and treatment-related leukemia. Med Pediatr Oncol. 2001;36:541–548.

    PubMed  CAS  Google Scholar 

  118. Relling MV, Rubnitz JE, Rivera GK, et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet. 1999;354:34–39.

    PubMed  CAS  Google Scholar 

  119. Relling MV, Yanishevski Y, Nemec J, et al. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia. 1998;12:346–352.

    PubMed  CAS  Google Scholar 

  120. Jenkinson H, Hawkins M. Secondary brain tumours in children with ALL. Lancet. 1999;354:1126.

    PubMed  CAS  Google Scholar 

  121. Stanulla M, Loning L, Welte K, et al. Secondary brain tumours in children with ALL. Lancet. 1999;354:1126–1127.

    PubMed  CAS  Google Scholar 

  122. Sharif S, Ferner R, Birch JM, et al. Second primary tumors in neurofibromatosis 1 patients treated for optic glioma: substantial risks after radiotherapy. J Clin Oncol. 2006;24:2570–2575.

    PubMed  Google Scholar 

  123. Hottinger AF, Khakoo Y. Update on the management of familial central nervous system tumor syndromes. Curr Neurol Neurosci Rep. 2007;7:200–207.

    PubMed  Google Scholar 

  124. van Leeuwen FE, Somers R, Taal BG, et al. Increased risk of lung cancer, non-Hodgkin's lymphoma, and leukemia following Hodgkin's disease. J Clin Oncol. 1989;7:1046–1058.

    PubMed  Google Scholar 

  125. Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst. 2002;94:182–192.

    PubMed  Google Scholar 

  126. van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J Natl Cancer Inst. 1995;87:1530–1537.

    PubMed  Google Scholar 

  127. Tucker MA, Murray N, Shaw EG, et al. Second primary cancers related to smoking and treatment of small-cell lung cancer. Lung Cancer Working Cadre. J Natl Cancer Inst. 1997;89:1782–1788.

    PubMed  CAS  Google Scholar 

  128. Inskip PD, Boice JD, Jr. Radiotherapy-induced lung cancer among women who smoke. Cancer. 1994;73:1541–1543.

    PubMed  CAS  Google Scholar 

  129. Neugut AI, Murray T, Santos J, et al. Increased risk of lung cancer after breast cancer radiation therapy in cigarette smokers. Cancer. 1994;73:1615–1620.

    PubMed  CAS  Google Scholar 

  130. Boivin JF. Smoking, treatment for Hodgkin's disease, and subsequent lung cancer risk. J Natl Cancer Inst. 1995;87:1502–1503.

    PubMed  CAS  Google Scholar 

  131. Landier W, Bhatia S, Eshelman DA, et al. Development of risk-based guidelines for pediatric cancer survivors: the Children's Oncology Group Long-Term Follow-Up Guidelines from the Children's Oncology Group Late Effects Committee and Nursing Discipline. J Clin Oncol. 2004;22:4979–4990.

    PubMed  Google Scholar 

  132. Laughlin-Richard N. Sun exposure and skin cancer prevention in children and adolescents. J Sch Nurs. 2000;16:20–26.

    PubMed  CAS  Google Scholar 

  133. Flanders WD, Rothman KJ. Interaction of alcohol and tobacco in laryngeal cancer. Am J Epidemiol. 1982;115:371–379.

    PubMed  CAS  Google Scholar 

  134. La Vecchia C, Negri E. The role of alcohol in oesophageal cancer in non-smokers, and of tobacco in non-drinkers. Int J Cancer. 1989;43:784–785.

    PubMed  Google Scholar 

  135. Emmons KM, Puleo E, Park E, et al. Peer-delivered smoking counseling for childhood cancer survivors increases rate of cessation: the partnership for health study. J Clin Oncol. 2005;23:6516–6523.

    PubMed  Google Scholar 

  136. Tyc VL, Hudson MM, Hinds P, et al. Tobacco use among pediatric cancer patients: recommendations for developing clinical smoking interventions. J Clin Oncol. 1997;15:2194–2204.

    PubMed  CAS  Google Scholar 

  137. Tyc VL, Lensing S, Klosky J, et al. A comparison of tobacco-related risk factors between adolescents with and without cancer. J Pediatr Psychol. 2005;30:359–370.

    PubMed  Google Scholar 

  138. Tyc VL, Throckmorton-Belzer L. Smoking rates and the state of smoking interventions for children and adolescents with chronic illness. Pediatrics. 2006;118:e471–e487.

    PubMed  Google Scholar 

  139. Green DM, Hyland A, Barcos MP, et al. Second malignant neoplasms after treatment for Hodgkin's disease in childhood or adolescence. J Clin Oncol. 2000;18:1492–1499.

    PubMed  CAS  Google Scholar 

  140. Davies SM. Subsequent malignant neoplasms in survivors of childhood cancer: Childhood Cancer Survivor Study (CCSS) studies. Pediatr Blood Cancer. 2007;48:727–730.

    PubMed  Google Scholar 

  141. Kaye FJ, Harbour JW. For whom the bell tolls: susceptibility to common adult cancers in retinoblastoma survivors. J Natl Cancer Inst. 2004;96:342–343.

    PubMed  Google Scholar 

  142. Kingston JE, Hawkins MM, Draper GJ, et al. Patterns of multiple primary tumours in patients treated for cancer during childhood. Br J Cancer. 1987;56:331–338.

    PubMed  CAS  Google Scholar 

  143. Le Deley MC, Leblanc T, Shamsaldin A, et al. Risk of secondary leukemia after a solid tumor in childhood according to the dose of epipodophyllotoxins and anthracyclines: a case-control study by the Societe Francaise d'Oncologie Pediatrique. J Clin Oncol. 2003;21:1074–1081.

    PubMed  Google Scholar 

  144. Wenzel CT, Halperin EC, Fisher SR. Second malignant neoplasms of the head and neck in survivors of retinoblastoma. Ear Nose Throat J. 2001;80:106, 9–12.

    PubMed  CAS  Google Scholar 

  145. Dunst J, Ahrens S, Paulussen M, et al. Second malignancies after treatment for Ewing's sarcoma: a report of the CESS-studies. Int J Radiat Oncol Biol Phys. 1998;42:379–384.

    PubMed  CAS  Google Scholar 

  146. Kuttesch JF, Jr., Wexler LH, Marcus RB, et al. Second malignancies after Ewing's sarcoma: radiation dose-dependency of secondary sarcomas. J Clin Oncol. 1996;14:2818–2825.

    PubMed  Google Scholar 

  147. Svahn-Tapper G, Garwicz S, Anderson H, et al. Radiation dose and relapse are predictors for development of second malignant solid tumors after cancer in childhood and adolescence: a population-based case-control study in the five Nordic countries. Acta Oncologica (Stockholm, Sweden). 2006;45:438–448.

    Google Scholar 

  148. Bhatia S, Sather HN, Pabustan OB, et al. Low incidence of second neoplasms among children diagnosed with acute lymphoblastic leukemia after 1983. Blood. 2002;99:4257–4264.

    PubMed  CAS  Google Scholar 

  149. Ronckers CM, Sigurdson AJ, Stovall M, et al. Thyroid cancer in childhood cancer survivors: a detailed evaluation of radiation dose response and its modifiers. Radiat Res. 2006;166:618–628.

    PubMed  CAS  Google Scholar 

  150. de Vathaire F, Francois P, Hill C, et al. Role of radiotherapy and chemotherapy in the risk of second malignant neoplasms after cancer in childhood. Br J Cancer. 1989;59:792–796.

    PubMed  Google Scholar 

  151. Hawkins MM, Wilson LM, Burton HS, et al. Radiotherapy, alkylating agents, and risk of bone cancer after childhood cancer. J Natl Cancer Inst. 1996;88:270–278.

    PubMed  CAS  Google Scholar 

  152. Breslow NE, Takashima JR, Whitton JA, et al. Second malignant neoplasms following treatment for Wilm's tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol. 1995;13:1851–1859.

    PubMed  CAS  Google Scholar 

  153. Menu-Branthomme A, Rubino C, Shamsaldin A, et al. Radiation dose, chemotherapy and risk of soft tissue sarcoma after solid tumours during childhood. Int J Cancer. 2004;110:87–93.

    PubMed  CAS  Google Scholar 

  154. Karlsson P, Holmberg E, Lundell M, et al. Intracranial tumors after exposure to ionizing radiation during infancy: a pooled analysis of two Swedish cohorts of 28,008 infants with skin hemangioma. Radiat Res. 1998;150:357–364.

    PubMed  CAS  Google Scholar 

  155. Little MP, de Vathaire F, Shamsaldin A, et al. Risks of brain tumour following treatment for cancer in childhood: modification by genetic factors, radiotherapy and chemotherapy. Int J Cancer. 1998;78:269–275.

    PubMed  CAS  Google Scholar 

  156. Kony SJ, de Vathaire F, Chompret A, et al. Radiation and genetic factors in the risk of second malignant neoplasms after a first cancer in childhood. Lancet. 1997;350:91–95.

    PubMed  CAS  Google Scholar 

  157. Kleinerman RA, Stovall M, Tarone RE, et al. Gene environment interactions in a cohort of irradiated retinoblastoma patients. Radiat Res. 2005;163:701–702.

    PubMed  CAS  Google Scholar 

  158. Guerin S, Guibout C, Shamsaldin A, et al. Concomitant chemo-radiotherapy and local dose of radiation as risk factors for second malignant neoplasms after solid cancer in childhood: a case-control study. Int J Cancer. 2007;120:96–102.

    PubMed  CAS  Google Scholar 

  159. Sagerman RH, Cassady JR, Tretter P, et al. Radiation induced neoplasia following external beam therapy for children with retinoblastoma. Am J Roentgenol Radium Ther Nucl Med. 1969;105:529–535.

    PubMed  CAS  Google Scholar 

  160. Loning L, Zimmermann M, Reiter A, et al. Secondary neoplasms subsequent to Berlin-Frankfurt-Munster therapy of acute lymphoblastic leukemia in childhood: significantly lower risk without cranial radiotherapy. Blood. 2000;95:2770–2775.

    PubMed  CAS  Google Scholar 

  161. Ron E, Modan B, Boice JD, Jr., et al. Tumors of the brain and nervous system after radiotherapy in childhood. N Engl J Med. 1988;319:1033–1039.

    PubMed  CAS  Google Scholar 

  162. Sadetzki S, Flint-Richter P, Ben-Tal T, et al. Radiation-induced meningioma: a descriptive study of 253 cases. J Neurosurg. 2002;97:1078–1082.

    PubMed  Google Scholar 

  163. Brada M, Ford D, Ashley S, et al. Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma. BMJ (Clin Res) ed. 1992;304:1343–1346.

    PubMed  CAS  Google Scholar 

  164. Shalet SM, Beardwell CG, MacFarlane IA, et al. Endocrine morbidity in adults treated with cerebral irradiation for brain tumours during childhood. Acta endocrinologica. 1977;84:673–680.

    PubMed  CAS  Google Scholar 

  165. Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys. 2006;65:1–7.

    PubMed  Google Scholar 

  166. Travis LB, Holowaty EJ, Bergfeldt K, et al. Risk of leukemia after platinum-based chemotherapy for ovarian cancer. N Engl J Med. 1999;340:351–357.

    PubMed  CAS  Google Scholar 

  167. Smith MA, Rubinstein L, Anderson JR, et al. Secondary leukemia or myelodysplastic syndrome after treatment with epipodophyllotoxins. J Clin Oncol. 1999;17:569–577.

    PubMed  CAS  Google Scholar 

  168. Smith MA, Rubinstein L, Ungerleider RS. Therapy-related acute myeloid leukemia following treatment with epipodophyllotoxins: estimating the risks. Med Pediatr Oncol. 1994;23:86–98.

    PubMed  CAS  Google Scholar 

  169. Hawkins MM, Wilson LM, Stovall MA, et al. Epipodophyllotoxins, alkylating agents, and radiation and risk of secondary leukaemia after childhood cancer. BMJ (Clin Res) ed. 1992;304:951–958.

    PubMed  CAS  Google Scholar 

  170. Klein G, Michaelis J, Spix C, et al. Second malignant neoplasms after treatment of childhood cancer. Eur J Cancer. 2003;39:808–817.

    PubMed  CAS  Google Scholar 

  171. Haas JF, Kittelmann B, Mehnert WH, et al. Risk of leukaemia in ovarian tumour and breast cancer patients following treatment by cyclophosphamide. Br J Cancer. 1987;55:213–218.

    PubMed  CAS  Google Scholar 

  172. Henderson TO, Whitton J, Stovall M, et al. Secondary sarcomas in childhood cancer survivors: a report from the Childhood Cancer Survivor Study. J Natl Cancer Inst. 2007;99:300–308.

    PubMed  Google Scholar 

  173. Hawkins MM. Risks of myeloid leukaemia in children treated for solid tumours. Lancet. 1990;336:887.

    PubMed  CAS  Google Scholar 

  174. Green DM, Zevon MA, Reese PA, et al. Second malignant tumors following treatment during childhood and adolescence for cancer. Med Pediatr Oncol. 1994;22:1–10.

    PubMed  CAS  Google Scholar 

  175. Draper GJ, Sanders BM, Kingston JE. Second primary neoplasms in patients with retinoblastoma. Br J Cancer. 1986;53:661–671.

    PubMed  CAS  Google Scholar 

  176. Gombos DS, Hungerford J, Abramson DH, et al. Secondary acute myelogenous leukemia in patients with retinoblastoma: is chemotherapy a factor? Ophthalmology. 2007;114:1378–1383.

    Google Scholar 

  177. Shannon KM, O'Connell P, Martin GA, et al. Loss of the normal NF1 allele from the bone marrow of children with type 1 neurofibromatosis and malignant myeloid disorders. N Engl J Med. 1994;330:597–601.

    PubMed  CAS  Google Scholar 

  178. Hoffmann L, Moller P, Pedersen-Bjergaard J, et al. Therapy-related acute promyelocytic leukemia with t(15;17) (q22;q12) following chemotherapy with drugs targeting DNA topoisomerase II. A report of two cases and a review of the literature. Ann Oncol. 1995;6:781–788.

    PubMed  CAS  Google Scholar 

  179. Bisogno G, Sotti G, Nowicki Y, et al. Soft tissue sarcoma as a second malignant neoplasm in the pediatric age group. Cancer. 2004;100:1758–1765.

    PubMed  Google Scholar 

  180. Pedersen-Bjergaard J, Sigsgaard TC, Nielsen D, et al. Acute monocytic or myelomonocytic leukemia with balanced chromosome translocations to band 11q23 after therapy with 4-epi-doxorubicin and cisplatin or cyclophosphamide for breast cancer. J Clin Oncol. 1992;10:1444–1451.

    PubMed  CAS  Google Scholar 

  181. Diamandidou E, Buzdar AU, Smith TL, et al. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas M.D. Anderson Cancer Center experience. J Clin Oncol. 1996;14:2722–2730.

    PubMed  CAS  Google Scholar 

  182. Sklar CA, Mertens AC, Mitby P, et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2002;87:3136–3141.

    PubMed  CAS  Google Scholar 

  183. Ergun-Longmire B, Mertens AC, Mitby P, et al. Growth hormone treatment and risk of second neoplasms in the childhood cancer survivor. J Clin Endocrinol Metab. 2006;91:3494–3498.

    PubMed  CAS  Google Scholar 

  184. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst. 1995;87:190–197.

    PubMed  CAS  Google Scholar 

  185. Pike MC, Spicer DV, Dahmoush L, et al. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev. 1993;15:17–35.

    PubMed  CAS  Google Scholar 

  186. Bosland MC. Sex steroids and prostate carcinogenesis: integrated, multifactorial working hypothesis. Ann N Y Acad Sci. 2006;1089:168–176.

    PubMed  CAS  Google Scholar 

  187. Schottenfeld DF, Joseph F, ed. Cancer Epidemiology and Prevention. 2nd ed: Oxford, USA: Oxford University Press; 1996.

    Google Scholar 

  188. Park SM, Lim MK, Jung KW, et al. Prediagnosis smoking, obesity, insulin resistance, and second primary cancer risk in male cancer survivors: National Health Insurance Corporation Study. J Clin Oncol. 2007;25:4835–4843.

    PubMed  Google Scholar 

  189. Irigaray P, Newby JA, Lacomme S, et al. Overweight/obesity and cancer genesis: More than a biological link. Biomed Pharmacotherapy. 2007;61:665–678.

    CAS  Google Scholar 

  190. McTiernan A. Obesity and cancer: the risks, science, and potential management strategies. Oncology (Williston Park, NY). 2005;19:871–881; discussion 81–82, 85–86.

    Google Scholar 

  191. Packer RJ, Boyett JM, Janss AJ, et al. Growth hormone replacement therapy in children with medulloblastoma: use and effect on tumor control. J Clin Oncol. 2001;19:480–487.

    PubMed  CAS  Google Scholar 

  192. Danoff BF, Cowchock FS, Marquette C, et al. Assessment of the long-term effects of primary radiation therapy for brain tumors in children. Cancer. 1982;49:1580–1586.

    PubMed  CAS  Google Scholar 

  193. Duffner PK, Horowitz ME, Krischer JP, et al. Postoperative chemotherapy and delayed radiation in children less than three years of age with malignant brain tumors. N Engl J Med. 1993;328:1725–1731.

    PubMed  CAS  Google Scholar 

  194. Stavrou T, Bromley CM, Nicholson HS, et al. Prognostic factors and secondary malignancies in childhood medulloblastoma. J Pediatr Hematol Oncol. 2001;23:431–436.

    PubMed  CAS  Google Scholar 

  195. Minniti G, Traish D, Ashley S, et al. Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years. J Clin Endocrinol Metab. 2005;90:800–804.

    PubMed  CAS  Google Scholar 

  196. Salminen E, Pukkala E, Teppo L. Second cancers in patients with brain tumours – impact of treatment. Eur J Cancer. 1999;35:102–105.

    PubMed  CAS  Google Scholar 

  197. Goldstein AM, Yuen J, Tucker MA. Second cancers after medulloblastoma: population-based results from the United States and Sweden. Cancer Causes Contr. 1997;8:865–871.

    CAS  Google Scholar 

  198. Hader WJ, Drovini-Zis K, Maguire JA. Primitive neuroectodermal tumors in the central nervous system following cranial irradiation: a report of four cases. Cancer. 2003;97:1072–1076.

    PubMed  Google Scholar 

  199. Barasch ES, Altieri D, Decker RE, et al. Primitive neuroectodermal tumor presenting as a delayed sequela to cranial irradiation and intrathecal methotrexate. Pediatr Neurol. 1988;4:375–378.

    PubMed  CAS  Google Scholar 

  200. Rittinger O, Kranzinger M, Jones R, et al. Malignant astrocytoma arising 10 years after combined treatment of craniopharyngioma. J Pediatr Endocrinol Metab. 2003;16:97–101.

    PubMed  CAS  Google Scholar 

  201. Kranzinger M, Jones N, Rittinger O, et al. Malignant glioma as a secondary malignant neoplasm after radiation therapy for craniopharyngioma: report of a case and review of reported cases. Onkologie. 2001;24:66–72.

    PubMed  CAS  Google Scholar 

  202. Liwnicz BH, Berger TS, Liwnicz RG, et al. Radiation-associated gliomas: a report of four cases and analysis of postradiation tumors of the central nervous system. Neurosurgery. 1985;17:436–445.

    PubMed  CAS  Google Scholar 

  203. Kantar M, Cetingul N, Kansoy S, et al. Radiotherapy-induced secondary cranial neoplasms in children. Childs Nerv Syst. 2004;20:46–49.

    PubMed  Google Scholar 

  204. Iyer RS, Soman CS, Nair CN, et al. Brain tumors following cure of acute lymphoblastic leukemia. Leukemia Lymphoma. 1994;13:183–186.

    PubMed  CAS  Google Scholar 

  205. Kitanaka C, Shitara N, Nakagomi T, et al. Postradiation astrocytoma. Report of two cases. J Neurosurg. 1989;70:469–474.

    PubMed  CAS  Google Scholar 

  206. Salvati M, Puzzilli F, Bristot R, et al. Post-radiation gliomas. Tumori. 1994;80:220–223.

    PubMed  CAS  Google Scholar 

  207. Salvati M, Artico M, Caruso R, et al. A report on radiation-induced gliomas. Cancer. 1991;67:392–397.

    PubMed  CAS  Google Scholar 

  208. Fontana M, Stanton C, Pompili A, et al. Late multifocal gliomas in adolescents previously treated for acute lymphoblastic leukemia. Cancer. 1987;60:1510–1518.

    PubMed  CAS  Google Scholar 

  209. Stragliotto G, Packer RJ, Rausen AR, et al. “Outcome of post-radiation secondary glioblastoma in children”. Med Pediatr Oncol. 1998;30:194–195.

    PubMed  CAS  Google Scholar 

  210. Postovsky S, Vlodavsky E, Eran A, et al. Secondary glioblastoma multiforme after treatment for primary choroid plexus carcinoma in childhood. J Pediatr Hematol Oncol. 2007;29:248–252.

    PubMed  Google Scholar 

  211. Tsang RW, Laperriere NJ, Simpson WJ, et al. Glioma arising after radiation therapy for pituitary adenoma. A report of four patients and estimation of risk. Cancer. 1993;72:2227–2233.

    PubMed  CAS  Google Scholar 

  212. Donson AM, Erwin NS, Kleinschmidt-DeMasters BK, et al. Unique molecular characteristics of radiation-induced glioblastoma. J Neuropathol Exp Neurol. 2007;66:740–749.

    PubMed  CAS  Google Scholar 

  213. Pui CH, Cheng C, Leung W, et al. Extended follow-up of long-term survivors of childhood acute lymphoblastic leukemia. N Engl J Med. 2003;349:640–649.

    PubMed  Google Scholar 

  214. Boljesikova E, Chorvath M. Radiation-induced meningiomas. Neoplasma. 2001;48:442–444.

    PubMed  CAS  Google Scholar 

  215. Harrison MJ, Wolfe DE, Lau TS, et al. Radiation-induced meningiomas: experience at the Mount Sinai Hospital and review of the literature. J Neurosurg. 1991;75:564–574.

    PubMed  CAS  Google Scholar 

  216. Soffer D, Pittaluga S, Feiner M, et al. Intracranial meningiomas following low-dose irradiation to the head. J Neurosurg. 1983;59:1048–1053.

    PubMed  CAS  Google Scholar 

  217. Korenkov AI, Imhof HG, Brandner S, et al. Growth retardation and bilateral cataracts followed by anaplastic meningioma 23 years after high-dose cranial and whole-body irradiation for acute lymphoblastic leukemia: case report and review of the literature. J Neuro-oncol. 2005;74:195–199.

    Google Scholar 

  218. Longstreth WT, Jr., Dennis LK, McGuire VM, et al. Epidemiology of intracranial meningioma. Cancer. 1993;72:639–648.

    PubMed  Google Scholar 

  219. Strojan P, Popovic M, Jereb B. Secondary intracranial meningiomas after high-dose cranial irradiation: report of five cases and review of the literature. Int J Radiat Oncol Biol Phys. 2000;48:65–73.

    PubMed  CAS  Google Scholar 

  220. Musa BS, Pople IK, Cummins BH. Intracranial meningiomas following irradiation – a growing problem? Br J Neurosurg. 1995;9:629–637.

    PubMed  CAS  Google Scholar 

  221. Dorfmuller G, Wurtz FG, Kleinert R, et al. Cerebral primitive neuro-ectodermal tumour following treatment of a unilateral retinoblastoma. Acta Neurochirurgica. 1997;139:749–755.

    PubMed  CAS  Google Scholar 

  222. Brustle O, Ohgaki H, Schmitt HP, et al. Primitive neuroectodermal tumors after prophylactic central nervous system irradiation in children. Association with an activated K-ras gene. Cancer. 1992;69:2385–2392.

    PubMed  CAS  Google Scholar 

  223. Shore RE, Albert RE, Reed M, et al. Skin cancer incidence among children irradiated for ringworm of the scalp. Radiat Res. 1984;100:192–204.

    PubMed  CAS  Google Scholar 

  224. Ron E, Modan B, Preston D, et al. Radiation-induced skin carcinomas of the head and neck. Radiat Res. 1991;125:318–325.

    PubMed  CAS  Google Scholar 

  225. Perkins JL, Liu Y, Mitby PA, et al. Nonmelanoma skin cancer in survivors of childhood and adolescent cancer: a report from the childhood cancer survivor study. J Clin Oncol. 2005;23:3733–3741.

    PubMed  Google Scholar 

  226. Levi F, Moeckli R, Randimbison L, et al. Skin cancer in survivors of childhood and adolescent cancer. Eur J Cancer. 2006;42:656–659.

    PubMed  Google Scholar 

  227. Armstrong BK, Kricker A. The epidemiology of UV induced skin cancer. J Photochem Photobiol. 2001;63:8–18.

    CAS  Google Scholar 

  228. Hildreth NG, Shore RE, Hempelmann LH, et al. Risk of extrathyroid tumors following radiation treatment in infancy for thymic enlargement. Radiat Res. 1985;102:378–391.

    PubMed  CAS  Google Scholar 

  229. Shore RE. Overview of radiation-induced skin cancer in humans. Int J Radiat Biol. 1990;57:809–827.

    PubMed  CAS  Google Scholar 

  230. Marin-Gutzke M, Sanchez-Olaso A, Berenguer B, et al. Basal cell carcinoma in childhood after radiation therapy: case report and review. Ann Plastic Surg. 2004;53:593–595.

    Google Scholar 

  231. Dinehart SM, Anthony JL, Pollack SV. Basal cell carcinoma in young patients after irradiation for childhood malignancy. Med Pediatr Oncol. 1991;19:508–510.

    PubMed  CAS  Google Scholar 

  232. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med. 2003;348:1681–1691.

    PubMed  Google Scholar 

  233. Swerdlow AJ, English J, MacKie RM, et al. Benign melanocytic naevi as a risk factor for malignant melanoma. BMJ (Clin Res) ed. 1986;292:1555–1559.

    PubMed  CAS  Google Scholar 

  234. Kraehn GM, Schartl M, Peter RU. Human malignant melanoma. A genetic disease? Cancer. 1995;75:1228–1237.

    PubMed  CAS  Google Scholar 

  235. Gorlin RJ. Nevoid basal cell carcinoma (Gorlin) syndrome. Genet Med. 2004;6:530–539.

    PubMed  Google Scholar 

  236. Traboulsi EI, Zimmerman LE, Manz HJ. Cutaneous malignant melanoma in survivors of heritable retinoblastoma. Arch Ophthalmol. 1988;106:1059–1061.

    PubMed  CAS  Google Scholar 

  237. Bataille V, Hiles R, Bishop JA. Retinoblastoma, melanoma and the atypical mole syndrome. Br J Dermatol. 1995;132:134–138.

    PubMed  CAS  Google Scholar 

  238. Albert LS, Sober AJ, Rhodes AR. Cutaneous melanoma and bilateral retinoblastoma. J Am Acad Dermatol. 1990;23:1001–1004.

    PubMed  CAS  Google Scholar 

  239. Belt PJ, Smithers M, Elston T. The triad of bilateral retinoblastoma, dysplastic naevus syndrome and multiple cutaneous malignant melanomas: a case report and review of the literature. Melanoma Res. 2002;12:179–182.

    PubMed  CAS  Google Scholar 

  240. Yoshihara T, Ikuta H, Hibi S, et al. Second cutaneous neoplasms after acute lymphoblastic leukemia in childhood. Int J Hematol. 1993;59:67–71.

    PubMed  CAS  Google Scholar 

  241. Guerin S, Dupuy A, Anderson H, et al. Radiation dose as a risk factor for malignant melanoma following childhood cancer. Eur J Cancer. 2003;39:2379–2386.

    PubMed  CAS  Google Scholar 

  242. Dickerman JD. The late effects of childhood cancer therapy. Pediatrics. 2007;119:554–568.

    PubMed  Google Scholar 

  243. Benton E, Tidman M. Cutaneous complications. In: Wallace WaG, DM, ed. Late Effects of Childhood Cancer. London, UK: Arnold; 2004:321–331.

    Google Scholar 

  244. Moll AC, Imhof SM, Bouter LM, et al. Second primary tumors in patients with hereditary retinoblastoma: a register-based follow-up study, 1945–1994. Int J Cancer. 1996;67:515–519.

    PubMed  CAS  Google Scholar 

  245. Green A, Smith P, McWhirter W, et al. Melanocytic naevi and melanoma in survivors of childhood cancer. Br J Cancer. 1993;67:1053–1057.

    PubMed  CAS  Google Scholar 

  246. Baird EA, McHenry PM, MacKie RM. Effect of maintenance chemotherapy in childhood on numbers of melanocytic naevi. BMJ (Clin Res) ed. 1992;305:799–801.

    PubMed  CAS  Google Scholar 

  247. de Wit PE, de Vaan GA, de Boo TM, et al. Prevalence of naevocytic naevi after chemotherapy for childhood cancer. Med Pediatr Oncol. 1990;18:336–338.

    PubMed  Google Scholar 

  248. Karagas MR, McDonald JA, Greenberg ER, et al. Risk of basal cell and squamous cell skin cancers after ionizing radiation therapy. For The Skin Cancer Prevention Study Group. J Natl Cancer Inst. 1996;88:1848–1853.

    PubMed  CAS  Google Scholar 

  249. Lichter MD, Karagas MR, Mott LA, et al. Therapeutic ionizing radiation and the incidence of basal cell carcinoma and squamous cell carcinoma. The New Hampshire Skin Cancer Study Group. Arch Dermatol. 2000;136:1007–1011.

    PubMed  CAS  Google Scholar 

  250. Cutuli B, Borel C, Dhermain F, et al. Breast cancer occurred after treatment for Hodgkin's disease: analysis of 133 cases. Radiother Oncol. 2001;59:247–255.

    PubMed  CAS  Google Scholar 

  251. Preston DL, Mattsson A, Holmberg E, et al. Radiation effects on breast cancer risk: a pooled analysis of eight cohorts. Radiat Res. 2002;158:220–235.

    PubMed  CAS  Google Scholar 

  252. Broeks A, Russell NS, Floore AN, et al. Increased risk of breast cancer following irradiation for Hodgkin's disease is not a result of ATM germline mutations. Int J Radiat Biol. 2000;76:693–698.

    PubMed  CAS  Google Scholar 

  253. Nichols KE, Heath JA, Friedman D, et al. TP53, BRCA1, and BRCA2 tumor suppressor genes are not commonly mutated in survivors of Hodgkin's disease with second primary neoplasms. J Clin Oncol. 2003;21:4505–4509.

    PubMed  CAS  Google Scholar 

  254. Nichols KE, Levitz S, Shannon KE, et al. Heterozygous germline ATM mutations do not contribute to radiation-associated malignancies after Hodgkin's disease. J Clin Oncol. 1999;17:1259.

    PubMed  CAS  Google Scholar 

  255. Cutuli B. In regard to Gaffney et al., IJROBP. 2001;49:539–546. Int J Radiat Oncol Biol Phys. 2002;52:272–274.

    Google Scholar 

  256. Gaffney DK, Hemmersmeier J, Holden J, et al. Breast cancer after mantle irradiation for Hodgkin's disease: correlation of clinical, pathologic, and molecular features including loss of heterozygosity at BRCA1 and BRCA2. Int J Radiat Oncol Biol Phys. 2001;49:539–546.

    PubMed  CAS  Google Scholar 

  257. Travis LB, Hill D, Dores GM, et al. Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst. 2005;97:1428–1437.

    PubMed  Google Scholar 

  258. Cutuli B. Radiation-induced breast cancer after treatment for Hodgkin's disease. J Clin Oncol. 1998;16:2285–2287.

    PubMed  CAS  Google Scholar 

  259. Yasui Y, Liu Y, Neglia JP, et al. A methodological issue in the analysis of second-primary cancer incidence in long-term survivors of childhood cancers. Am J Epidemiol. 2003;158:1108–1113.

    PubMed  Google Scholar 

  260. Kaste SC, Hudson MM, Jones DJ, et al. Breast masses in women treated for childhood cancer: incidence and screening guidelines. Cancer. 1998;82:784–792.

    PubMed  CAS  Google Scholar 

  261. de Vathaire F, Hardiman C, Shamsaldin A, et al. Thyroid carcinomas after irradiation for a first cancer during childhood. Arch Int Med. 1999;159:2713–2719.

    Google Scholar 

  262. Acharya S, Sarafoglou K, LaQuaglia M, et al. Thyroid neoplasms after therapeutic radiation for malignancies during childhood or adolescence. Cancer. 2003;97:2397–2403.

    PubMed  Google Scholar 

  263. Schlumberger M, Cailleux AF, Suarez HG, et al. Irradiation and second cancers. The thyroid as a case in point. Comptes rendus de l'Academie des Sciences. 1999;322:205–213.

    PubMed  CAS  Google Scholar 

  264. Black P, Straaten A, Gutjahr P. Secondary thyroid carcinoma after treatment for childhood cancer. Med Pediatr Oncol. 1998;31:91–95.

    PubMed  CAS  Google Scholar 

  265. Bhatia S, Ramsay NK, Bantle JP, et al. Thyroid Abnormalities after Therapy for Hodgkin's Disease in Childhood. Oncologist. 1996;1:62–67.

    PubMed  Google Scholar 

  266. Agartan CA, Ustundag N, Gurleyik G, et al. Secondary thyroid carcinoma after treatment of yolk sac tumor. J Pediatr Hematol Oncol. 2004;26:77.

    PubMed  Google Scholar 

  267. Fugazzola L, Pilotti S, Pinchera A, et al. Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident. Cancer Res. 1995;55:5617–5620.

    PubMed  CAS  Google Scholar 

  268. Ito T, Seyama T, Iwamoto KS, et al. Activated RET oncogene in thyroid cancers of children from areas contaminated by Chernobyl accident. Lancet. 1994;344:259.

    PubMed  CAS  Google Scholar 

  269. Klugbauer S, Lengfelder E, Demidchik EP, et al. High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident. Oncogene. 1995;11:2459–2467.

    PubMed  CAS  Google Scholar 

  270. Caudill CM, Zhu Z, Ciampi R, et al. Dose-dependent generation of RET/PTC in human thyroid cells after in vitro exposure to gamma-radiation: a model of carcinogenic chromosomal rearrangement induced by ionizing radiation. J Clin Endocrinol Metab. 2005;90:2364–2369.

    PubMed  CAS  Google Scholar 

  271. Gray L. Radiation Biology and Cancer. In: Cellular radiation biology: A collection of works presented at the 18th Annual Symposium on Experimental Cancer Research 1964, Baltimore: Williams and Wilkins; 1965:7–25.

    Google Scholar 

  272. Ron E. Cancer risks from medical radiation. Health Phys. 2003;85:47–59.

    PubMed  CAS  Google Scholar 

  273. Whatley WS, Thompson JW, Rao B. Salivary gland tumors in survivors of childhood cancer. Otolaryngol Head Neck Surg. 2006;134:385–388.

    PubMed  Google Scholar 

  274. Lorigan P, Radford J, Howell A, et al. Lung cancer after treatment for Hodgkin's lymphoma: a systematic review. Lancet Oncol. 2005;6:773–779.

    PubMed  Google Scholar 

  275. Kleinerman RA, Tarone RE, Abramson DH, et al. Hereditary retinoblastoma and risk of lung cancer. J Natl Cancer Inst. 2000;92:2037–2039.

    PubMed  CAS  Google Scholar 

  276. Horowitz JM, Park SH, Bogenmann E, et al. Frequent inactivation of the retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. Proc Natl Acad Sci USA. 1990;87:2775–2779.

    PubMed  CAS  Google Scholar 

  277. Xu HJ, Hu SX, Cagle PT, et al. Absence of retinoblastoma protein expression in primary non-small cell lung carcinomas. Cancer Res. 1991;51:2735–2739.

    PubMed  CAS  Google Scholar 

  278. Cance WG, Brennan MF, Dudas ME, et al. Altered expression of the retinoblastoma gene product in human sarcomas. N Engl J Med. 1990;323:1457–1462.

    PubMed  CAS  Google Scholar 

  279. Shearer P, Kapoor G, Beckwith JB, et al. Secondary acute myelogenous leukemia in patients previously treated for childhood renal tumors: a report from the National Wilms Tumor Study Group. J Pediatr Hematol Oncol. 2001;23:109–111.

    PubMed  CAS  Google Scholar 

  280. Thirman MJ, Larson RA. Therapy-related myeloid leukemia. Hematol/Oncol Clinics North America. 1996;10:293–320.

    CAS  Google Scholar 

  281. Kaldor JM, Day NE, Clarke EA, et al. Leukemia following Hodgkin's disease. N Engl J Med. 1990;322:7–13.

    PubMed  CAS  Google Scholar 

  282. Bhatia S, Krailo MD, Chen Z, et al. Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group. Blood. 2007;109:46–51.

    PubMed  CAS  Google Scholar 

  283. Sandoval C, Pui CH, Bowman LC, et al. Secondary acute myeloid leukemia in children previously treated with alkylating agents, intercalating topoisomerase II inhibitors, and irradiation. J Clin Oncol. 1993;11:1039–1045.

    PubMed  CAS  Google Scholar 

  284. Kantarjian HM, Keating MJ. Therapy-related leukemia and myelodysplastic syndrome. Semin Oncol. 1987;14:435–443.

    PubMed  CAS  Google Scholar 

  285. Casteels K, Renard M, Van Gool S, et al. Secondary acute lymphoblastic leukemia in a child three years after treatment for medulloblastoma. Med Pediatr Oncol. 2001;36:390–391.

    PubMed  CAS  Google Scholar 

  286. Latagliata R, Petti MC, Fenu S, et al. Therapy-related myelodysplastic syndrome-acute myelogenous leukemia in patients treated for acute promyelocytic leukemia: an emerging problem. Blood. 2002;99:822–824.

    PubMed  CAS  Google Scholar 

  287. Rubin CM, Le Beau MM. Cytogenetic abnormalities in childhood acute lymphoblastic leukemia. Am J Pediatr Hematol/Oncol. 1991;13:202–216.

    CAS  Google Scholar 

  288. Su YW, Chang MC, Chiang MF, et al. Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma. J Neuro-oncol. 2005;71:315–318.

    Google Scholar 

  289. Pedersen-Bjergaard J, Andersen MK, Johansson B. Balanced chromosome aberrations in leukemias following chemotherapy with DNA-topoisomerase II inhibitors. J Clin Oncol. 1998;16:1897–1898.

    PubMed  CAS  Google Scholar 

  290. Smith G, Stanley LA, Sim E, et al. Metabolic polymorphisms and cancer susceptibility. Cancer Surv. 1995;25:27–65.

    PubMed  CAS  Google Scholar 

  291. Raunio H, Husgafvel-Pursiainen K, Anttila S, et al. Diagnosis of polymorphisms in carcinogen-activating and inactivating enzymes and cancer susceptibility – a review. Gene. 1995;159:113–121.

    PubMed  CAS  Google Scholar 

  292. Pedersen-Bjergaard J, Pedersen M, Roulston D, et al. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood. 1995;86:3542–3552.

    PubMed  CAS  Google Scholar 

  293. Pedersen-Bjergaard J, Andersen MK. Secondary or therapy-related MDS and AML and their chromosome aberrations: important to study but difficult to establish causality. Haematologica. 1998;83:481–482.

    PubMed  CAS  Google Scholar 

  294. Mistry AR, Felix CA, Whitmarsh RJ, et al. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med. 2005;352:1529–1538.

    PubMed  CAS  Google Scholar 

  295. Pui CH, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med. 1991;325:1682–1687.

    PubMed  CAS  Google Scholar 

  296. Pui CH, Relling MV, Rivera GK, et al. Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases. Leukemia. 1995;9:1990–1996.

    PubMed  CAS  Google Scholar 

  297. Fisher PG. Rethinking brain tumors in babies and more. Ann Neurol. 1998;44:300–302.

    PubMed  CAS  Google Scholar 

  298. Estey EH. Prognosis and therapy of secondary myelodysplastic syndromes. Haematologica. 1998;83:543–549.

    PubMed  CAS  Google Scholar 

  299. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood. 1997;89:3323–3329.

    PubMed  CAS  Google Scholar 

  300. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood. 2000;96:4075–4083.

    PubMed  CAS  Google Scholar 

  301. Anderson JE, Gooley TA, Schoch G, et al. Stem cell transplantation for secondary acute myeloid leukemia: evaluation of transplantation as initial therapy or following induction chemotherapy. Blood. 1997;89:2578–2585.

    PubMed  CAS  Google Scholar 

  302. Witherspoon RP, Deeg HJ. Allogeneic bone marrow transplantation for secondary leukemia or myelodysplasia. Haematologica. 1999;84:1085–1087.

    PubMed  CAS  Google Scholar 

  303. Zuna J, Cave H, Eckert C, et al. Childhood secondary ALL after ALL treatment. Leukemia. 2007;21:1431–1435.

    PubMed  CAS  Google Scholar 

  304. Lehrnbecher T, Deinlein F, Marx A, et al. Mediastinal T-cell lymphoma in a boy 7 years after treatment of supratentorial primitive neuroectodermal tumor. J Pediatr Hematol Oncol. 2003;25:657–659.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Oncology and Stem Cell Transplantation, Children’s Memorial Hospital, Chicago, IL, USA

    Joanna L. Weinstein

  2. Pediatric Hematology/Oncology, Kosair Children’s Hospital, University of Louisville, 40202, Louisville, KY, USA

    Kanyalakshmi Ayyanar

  3. Pediatric Neuro-Oncology, The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, NC, USA

    Melody A. Watral MSN, RN, CPNP, CPON

Authors
  1. Joanna L. Weinstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kanyalakshmi Ayyanar
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Melody A. Watral MSN, RN, CPNP, CPON
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Joanna L. Weinstein .

Editor information

Editors and Affiliations

  1. Dept. Pediatrics, Children's Memorial Hospital, Children's Plaza 2300, Chicago, 30614, U.S.A.

    Stewart Goldman

  2. Dana-Farber Cancer Institute, Harvard Medical School, Binney St. 44, Boston, 02115, U.S.A.

    Christopher D. Turner

Rights and permissions

Reprints and permissions

Copyright information

© 2009 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Weinstein, J.L., Ayyanar, K., Watral, M.A. (2009). Secondary Neoplasms Following Treatment for Brain Tumors. In: Goldman, S., Turner, C. (eds) Late Effects of Treatment for Brain Tumors. Cancer Treatment and Research, vol 150. Springer, Boston, MA. https://doi.org/10.1007/b109924_16

Download citation

  • DOI: https://doi.org/10.1007/b109924_16

  • Published:

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-0-387-77102-1

  • Online ISBN: 978-0-387-77103-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation